alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 601–625 of 696 studies with an author at Mayo Clinic (US) (page 25 of 28) · 30,580 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 16,054 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

ApoE (Apolipoprotein E) in Brain Pericytes Regulates Endothelial Function in an Isoform-Dependent Manner by Modulating Basement Membrane Components

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Arteriosclerosis, thrombosis, and vascular biology 2019-10-31

ApoE4 impairs pericyte-mediated basement membrane formation, potentially contributing to the cerebrovascular effects of apoE4. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects

✓ Peer-reviewed alzhub usefulness score 45 out of 100. NeuroImage 2010-01-18

We used a previously validated automated machine learning algorithm based on adaptive boosting to segment the hippocampi in baseline and 12-month follow-up 3D T1-weighted brain MRIs of 150 cognitively normal elderly (NC), 245 mild cognitive impairment (MCI) and 97 Dementia of the Alzheimer's type (DAT) ADNI subjects. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The familial dementia BRI2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production

✓ Peer-reviewed alzhub usefulness score 45 out of 100. The Journal of biological chemistry 2005-06-27

Alzheimer disease (AD), the most common senile dementia, is characterized by amyloid plaques, vascular amyloid, neurofibrillary tangles, and progressive neurodegeneration. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice

✓ Peer-reviewed alzhub usefulness score 45 out of 100. The Journal of biological chemistry 2007-06-07

The amino acid sequence of amyloid precursor protein (APP) is highly conserved, and age-related A beta aggregates have been described in a variety of vertebrate animals, with the notable exception of mice and rats. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Assessing the Impact of Sociodemographic Factors on Artificial Intelligence Models in Predicting Dementia: Retrospective Cohort Study

✓ Peer-reviewed alzhub usefulness score 45 out of 100. JMIR Medical Informatics 2026-01-07

Across both cohorts, individuals with lower SES generally exhibited higher BERs (worse performance) than high SES groups, confirming the presence of bias. 5 key findings →

Participants: 3,041 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Associations between neuropsychiatric symptoms and pathology in clinicopathologically defined Alzheimer's disease, Alzheimer's disease with Lewy bodies, and dementia with Lewy bodies

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of Alzheimer s Disease 2025-03-14

Early NPS burden as well as NPS severity progression rate, independently of cognitive status, might be useful clinical metrics and may help predict underlying pathological diagnoses. 3 key findings →

Participants: 75 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study population

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Alzheimer disease and associated disorders 2009-10-01

The groups of individuals who agreed to participate in the imaging substudies of AD trials were remarkably comparable to the comparison groups at baseline on a wide range of demographic and clinical measures; there seems to be a minimal effect of self-selection bias. 4 key findings →

Participants: 166 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Exercise and metformin counteract altered mitochondrial function in the insulin-resistant brain

✓ Peer-reviewed alzhub usefulness score 44 out of 100. JCI insight 2019-09-19

Insulin resistance associates with increased risk for cognitive decline and dementia; however, the underpinning mechanisms for this increased risk remain to be fully defined. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Heritability of leukoaraiosis in hypertensive sibships

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Hypertension (Dallas, Tex. : 1979) 2004-01-12

Ischemic damage to the subcortical white matter of the brain, referred to as leukoaraiosis, is a frequent complication of hypertension-related microvascular disease and contributes to the risk of stroke and vascular dementia. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Neurobiology of disease 2022-03-28

However, it remains unknown whether white matter (WM) decline due to AD is associated with specific Tau phosphorylation site(s). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Neurobiology of aging 2010-06-09

Cerebrospinal fluid (CSF) and structural magnetic resonance imaging (MRI) show patterns of change in Alzheimer's disease (AD) that precede dementia. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Differential associations of core and non-core plasma biomarkers with cognitive performance in Black adults

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of Alzheimer s Disease 2026-05-27

Non-core NfL and GFAP biomarkers are associated with both cross-sectional and longitudinal cognitive performance. 5 key findings →

Design: cross-sectional Participants: 334 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Exploratory factor and network analysis of 43 inflammatory plasma biomarkers and cognitive performance in Black adults

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of Alzheimer s Disease 2026-09-02

BackgroundSystemic inflammation has been implicated in cognitive aging and neurodegeneration; however, inflammatory biomarkers are expressed in coordinated patterns rather than as isolated markers. 4 key findings →

Design: cross-sectional Participants: 334 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Imaging‐neuropathology evaluation of Amyloid Related Imaging Abnormality sulcal effusion in a DIAN‐TU‐001 participant treated with gantenerumab

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Alzheimer s & Dementia 2025-12-01

Overall PiB-PET uptake increased during the first two years (before ARIA-E) and decreased during the last two years (including ARIA-E episodes) (0.03±0.05 vs. -0.04±0.04 SUVR/year, p-value=0.01, Figure 2). 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The Impact of Delirium on Hospitalized Patients With COPD Exacerbation: Insights From the National In-Patient Sample

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Respiratory Care 2025-05-09

A total of 8,062,333 subjects hospitalized with COPD exacerbation were included, of whom 574,005 (7.2%) had a diagnosis of delirium. 5 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,580 records, built mostly from automated pulls of Europe PMC (64.7% of the library) and OpenAlex (16.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events